Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000148) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE Etevritamab
|
|||||
| Synonyms |
AMG-596; AMG596
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I; Discontinued | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] , [2] , [3] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Stimulator | Glioblastoma [ICD-11: XH7F82] | N.A. | Amgen | [1] , [2] , [3] | |
| Epidermal growth factor receptor | Stimulator | Glioblastoma [ICD-11: XH7F82] | N.A. | Amgen | [1] , [2] , [3] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03296696 | Click to show the Detail | |||||
| Indication | Glioblastoma; Malignant Glioma | |||||
| Phase | Phase I | |||||
| Title | Phase I/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII) | |||||
| Status | Active, not recruiting | |||||
| Sponsor | Amgen | |||||
| References |
|---|